08.10 15:36 | dpa-AFX: Astellas Receives Option To License AVB-101 |
08.10 15:31 | dpa-AFX: *AVIADOBIO SECURES $20 MLN EQUITY INVESTMENT AND POTENTIAL $2.18 BLN IN FUTURE PAYMENTS FROM ASTELLAS |
08.10 15:30 | dpa-AFX: *ASTELLAS AND AVIADOBIO SIGN LICENSE AGREEMENT FOR GENE THERAPY AVB-101 TARGETING FRONTOTEMPORAL DEMENTIA |
20.09 17:19 | dpa-AFX: Astellas Gets European Commission Approval For VYLOY For Advanced Gastric Cancer |
20.09 15:20 | dpa-AFX: *ASTELLAS GETS EUROPEAN COMMISSION APPROVAL FOR VYLOY WITH CHEMOTHERAPY FOR ADVANCED GASTRIC CANCER |
19.09 02:44 | dpa-AFX: Astellas Announces FDA Listing Of DIGITIVA For Heart Failure Management |
11.09 08:22 | dpa-AFX: *ASTELLAS PHARMA TO HIGHLIGHT NEW DATA FROM ACROSS APPROVED AND INVESTIGATIONAL CANCER THERAPIES AT ESMO 2024 |
28.08 03:39 | dpa-AFX: Astellas : EC Approves PADCEV Combination For First-Line Treatment Of Advanced Urothelial Cancer |
27.08 09:11 | dpa-AFX: *ASTELLAS BEGINS PHASE 3 STUDY OF FEZOLINETANT FOR VMS IN WOMEN WITH BREAST CANCER RECEIVING ADJUVANT ENDOCRINE THERAPY |
20.08 05:19 | dpa-AFX: Astellas : China Approves Padcev For Treatment Of Locally Advanced Or Metastatic Urothelial Cancer |
28.07 05:23 | dpa-AFX: Astellas: Zolbetuximab Combo Gets Positive CHMP Opinion In Advanced Gastric &Gastroesophageal Cancer |
22.07 07:50 | dpa-AFX: Astellas, Osaka University To Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy |
22.07 07:41 | dpa-AFX: *ASTELLAS PHARMA, OSAKA UNIVERSITY COLLABORATE TO DEVELOP PLURIPOTENT STEM CELL-DERIVED CARTILAGE ORGANOID CELL THERAPY |
31.05 05:07 | dpa-AFX: FDA Acknowledges Astellas Pharma's Resubmission Of BLA For Zolbetuximab |
02.05 04:04 | dpa-AFX: Astellas, Poseida Collaborate To Develop Novel Allogeneic Cell Therapies In Oncology |
26.04 09:58 | MÄRKTE ASIEN/Freundlich - Yen lotet neue Tiefs aus |
25.04 12:51 | dpa-AFX: Astellas Pharma Annual Net Plunges, But Revenue Climbs; Expects 2024 Result To Improve |
25.04 11:13 | dpa-AFX: *ASTELLAS PHARMA FY REVENUE UP 5.6% TO 1.60 TRLN YEN |
24.04 02:57 | dpa-AFX: European Commission Approves Astellas' Xtandi For Recurrent Early Prostate Cancer Treatment |
24.04 02:29 | dpa-AFX: *EUROPEAN COMMISSION APPROVES ASTELLAS' XTANDI FOR RECURRENT EARLY PROSTATE CANCER TREATMENT EXPANSION |
|